INNOVATIVE BIOLOGICS

Innovative Biologics (IBI) is an anti-infective small molecule drug discovery and development company targeting microbes producing pore-forming toxins, such as MRSA and Hepatitis C. Many pathogens utilize the formation of pores in the membranes of target cells in the process of infection. IBI has developed the CycloPlex™ platform to identify compounds which inhibit their action, based on blocking the target pore with molecules having the same symmetry as the pore itself, using ß-cyclodextrin as a scaffold.